hydroxychloroquine has been researched along with trametinib in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 5 (83.33) | 2.80 |
| Authors | Studies |
|---|---|
| Aleman, TS; Amaravadi, RK; Bowman, S; Edelstein, ID; Gangadhar, TC; Huang, A; Kim, BJ; Mitnick, S; Nichols, CW; Nti, AA; Sandhu, HS; Schuchter, LM; Serrano, LW; Song, D; Uyhazi, KE; Zhou, EJ | 1 |
| Castria, TB; Fernandes, GS; Jardim, DLF; Marchetti, KR; Xavier, CB | 1 |
| Aleman, TS; Amaravadi, RK; Ansstas, G; Carberry, M; Chandra, S; Frey, N; Giles, L; Gimotty, PA; Groisberg, R; Hernandez-Aya, LF; Huang, AC; Karakousis, GC; Kim, BJ; Kossenkov, A; Linette, GP; Mehnert, JM; Mick, R; Mitchell, TC; Mitnick, S; Schuchter, LM; Silk, AW; Sosman, JA | 1 |
| Awada, G; Fasolino, G; Kruse, V; Neyns, B; Schwarze, JK; Tijtgat, J | 1 |
| Affolter, K; Gudipaty, S; Kinsey, C; McMahon, M; Rohweder, R; Schuman, S; Silva, D; Silvis, MR; Truong, A; Yap, J | 1 |
| Bai, C; Cheng, Y; Ge, Y; Li, X; Tang, H; Wang, Y; You, T | 1 |
3 trial(s) available for hydroxychloroquine and trametinib
| Article | Year |
|---|---|
FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial.
Topics: Adult; Aged; Antineoplastic Agents; Enzyme Inhibitors; Female; Humans; Hydroxychloroquine; Imidazoles; Macula Lutea; Male; MAP Kinase Kinase 1; Melanoma; Middle Aged; Oximes; Photoreceptor Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Retinal Diseases; Retinal Pigment Epithelium | 2019 |
BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Humans; Hydroxychloroquine; Imidazoles; Melanoma; Mitogen-Activated Protein Kinase Kinases; Mutation; Oximes; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones | 2022 |
A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Hydroxychloroquine; Imidazoles; Immune Checkpoint Inhibitors; Melanoma; Mitogen-Activated Protein Kinase Kinases; Mutation; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Skin Neoplasms | 2022 |
3 other study(ies) available for hydroxychloroquine and trametinib
| Article | Year |
|---|---|
Trametinib and Hydroxychloroquine (HCQ) Combination Treatment in KRAS-Mutated Advanced Pancreatic Adenocarcinoma: Detailed Description of Two Cases.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Hydroxychloroquine; Male; MAP Kinase Signaling System; Middle Aged; Mutation; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Proto-Oncogene Proteins p21(ras); Pyridones; Pyrimidinones; Treatment Outcome | 2021 |
MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by CDK4/6 and lysosomal inhibition.
Topics: Carcinoma, Pancreatic Ductal; Chloroquine; Cyclin-Dependent Kinase 4; Humans; Hydroxychloroquine; Lysosomes; Pancreatic Neoplasms | 2023 |
A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Therapy, Combination; Humans; Hydroxychloroquine; Pancreatic Neoplasms; Protein Kinase Inhibitors | 2023 |